language flag

English

  • language flag

    English

  • language flag

    German

  • language flag

    Italian

  • language flag

    Spanish

Therakos Logo - Dark
Languages:
Therakos e-learning platform
  1. Home
  2. Therakos Institute
  3. Ask the Expert
  4. View our Experts
TKS Institute TM CMYK 2022 WTE

View our Experts

Prof Markus Barten

Prof Markus Barten

Speciality:
Solid Organ Transplantation
Institution:
University Heart & Vascular Center Hamburg
See full profile
Prof Emmanuella Guenova

Prof Emmanuella Guenova

Speciality:
Dermatology
Institution:
University Hospital Lausanne
See full profile
Prof Max Schlaak

Prof Max Schlaak

Speciality:
Dermatology
Institution:
Charité-Universitätsmedizin Berlin, Germany
See full profile
Prof Jean Francois Augusto

Prof Jean Francois Augusto

Speciality:
Solid Organ Transplantation
Institution:
Angers University Hospital
See full profile
Prof Christian Benden

Prof Christian Benden

Speciality:
Solid Organ Transplantation
Institution:
Kinderarzthaus AG
See full profile
Charlotta Besev

Charlotta Besev

Speciality:
ECP Service and Patient Access
Institution:
Akademiska sjukhuset Uppsala
See full profile
Dr James Griffin

Dr James Griffin

Speciality:
Hematology
Institution:
Bristol Haematology & Oncology Centre
See full profile
Prof Peter Jaksch

Prof Peter Jaksch

Speciality:
Solid Organ Transplantation
Institution:
Medical University of Vienna
See full profile
Prof Robert Knobler

Prof Robert Knobler

Speciality:
Dermatology
Institution:
Medical University of Vienna
See full profile
Dr Wolfgang Mayer

Dr Wolfgang Mayer

Speciality:
Hematology
Institution:
Tirol Kliniken, Innsbruck
See full profile
Prof Zinaida Peric

Prof Zinaida Peric

Speciality:
Hematology
Institution:
University Hospital Centre Zagreb
See full profile
Dr Nicola Piccirillo

Dr Nicola Piccirillo

Speciality:
Hematology/ECP Service and Patient Access
Institution:
Fondazione Policlinico Universitario A. Gemelli Rome
See full profile
Alba Pons

Alba Pons

Speciality:
ECP Service and Patient Access
Institution:
Oslo University Hospital
See full profile
Prof Julia Scarisbrick

Prof Julia Scarisbrick

Speciality:
Dermatology
Institution:
University Hospital Birmingham
See full profile
Prof Eggert Stockfleth

Prof Eggert Stockfleth

Speciality:
Systemic Sclerosis
Institution:
St. Josef-Hospital, Ruhr-Universität Bochum, Germany
See full profile
Prof Daniel Wolff

Prof Daniel Wolff

Speciality:
Hematology
Institution:
University Hospital Regensburg
See full profile
Prof Nina Worel

Prof Nina Worel

Speciality:
Hematology
Institution:
Medical University of Vienna
See full profile

Request to book an appointment

To book an appointment, please make sure you are logged in

Register now

or

You are leaving the THERAKOS.EU website.
Therakos does not review or control the content of non-Therakos websites, and this hyperlink does not constitute an endorsement by Therakos of the site’s content. Therakos privacy procedures do not apply to the owners of a non-Therakos website.

Important Safety Information
For the TherakosTM Photopheresis
Procedure

Indications

The THERAKOSTM CELLEXTM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOSTM Photopheresis is contraindicated in:

  • Patients possessing a specific history of a light sensitive disease.
  • Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm3.
  • Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOSTM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

  • Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
  • Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
  • When prescribing and administering THERAKOSTM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

  • Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
  • Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
  • Treatment frequency exceeding labelling recommendations may result in anaemia.
  • Venous access carries a small risk of infection and pain.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

  • Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
  • Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
  • Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
  • Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

  • Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
  • Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
  • Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
  • Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.

This website is not intended for healthcare professionals based in US, France and Canada.

Please verify your status below.

I am a healthcare professional and

I am eligible to access this part of the website

I am not a healthcare professional.

I would like to return to the homepage

This website is not intended for residents
based in the US, France or Canada.

PLEASE CLICK HERE TO ENTER

If you are a French resident, please visit www.therakos.fr

Applications for the 2022 EIA are now closed.
The 2022 ECP Immunomodulation Investigator Award has been awarded to Professor Andrew Fisher, Professor of Respiratory Transplant Medicine at Newcastle University, and Honorary Consultant Respiratory and Transplant Physician at The Newcastle upon Tyne Hospitals NHS Foundation Trust's Institute of Transplantation. The objective of his project is to perform an in depth mechanistic assessment of Extracorporeal Photopheresis (ECP) treatment in patients suffering from Chronic lung Allograft Dysfunction (CLAD).

Full details are available on our press release page.

Copy the link to share with the HCP by clicking on the button below

 
THANK YOU FOR YOUR MESSAGE
We will take care of your request and get in contact with you soon
 
THANK YOU FOR YOUR APPLICATION
We can confirm we have received your submission.
 
AUTHORISATION

The Therakos e-learning platform wants to access the following information:

Your basic public profile
Your public email address

Please click the below button to authorise it

WELCOME TO THERAKOS.EU MY AREA
Forgot your password? Click Here
Not yet registered?
WELCOME TO THERAKOS.EU MY AREA
Forgot your password?